Evidence map›Paper›PMID 34356494›Full record

ArticleBiology2021

Molecular and Pathological Profiling of Corresponding Treatment-Naïve and Neoadjuvant Pazopanib-Treated High-Risk Soft Tissue Sarcoma Samples of the GISG-04/NOPASS Study.

Timo Gaiser, Christian Sauer, Alexander Marx, Jens Jakob, Bernd Kasper, Peter Hohenberger, Daniela Hirsch, Ulrich Ronellenfitsch

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Timo GaiserInstitute of Pathology, University Medical Centre Mannheim, University of Heidelberg, 68305 Mannheim, Germany.ORCID 0000-0002-6022-073X
Christian SauerInstitute of Pathology, University Medical Centre Mannheim, University of Heidelberg, 68305 Mannheim, Germany.
Alexander MarxInstitute of Pathology, University Medical Centre Mannheim, University of Heidelberg, 68305 Mannheim, Germany.
Jens JakobDepartment of General, Visceral and Child Surgery, University Medical Center Göttingen, 37075 Göttingen, Germany.
Bernd KasperSarcoma Unit, Interdisciplinary Tumor Center Mannheim, Mannheim University Medical Center, 68305 Mannheim, Germany.ORCID 0000-0001-8425-8356
Peter HohenbergerDivision of Surgical Oncology and Thoracic Surgery, University Medical Center Mannheim, 68167 Mannheim, Germany.ORCID 0000-0001-5359-5923
Daniela HirschInstitute of Pathology, University Medical Centre Mannheim, University of Heidelberg, 68305 Mannheim, Germany.
Ulrich RonellenfitschDepartment of Abdominal, Vascular, and Endocrine Surgery, University Hospital Halle (Saale), 06120 Halle (Saale), Germany.ORCID 0000-0003-1107-813X
Heidelberg University · DEUniversitätsmedizin Göttingen · DEUniversity Hospital in Halle · DE

Funding

GlaxoSmithKlineMedical Faculty of the Martin-Luther-University Halle-Wittenberg Advanced Clinician Scientist ProgramNovartis
6 · The paper itself

Abstract

In the framework of the German Interdisciplinary Sarcoma Group GISG-04/NOPASS trial, we evaluated soft tissue sarcoma samples taken before and after neoadjuvant pazopanib therapy using histopathology and next generation sequencing (NGS) to find potential predictive biomarkers. We also aimed to improve the genetically based sarcoma classification and to elucidate additional potentially druggable mutations. In total, 30 tumor samples from 18 patients consisting of 12 pre-therapeutic biopsies and 18 resection specimens following neoadjuvant pazopanib therapy were available for analyses. NGS was performed with the Oncomine Focus Assay (Ion Torrent) covering 0.03 Mb of DNA and enabled the detection of genetic variants in 52 cancer-relevant genes. Pathological analysis showed significant regression (≥50%) after pazopanib treatment in only one undifferentiated (pleomorphic) sarcoma. NGS analyses revealed a very high frequency of

Indexed as

BRAF V600ECDK4MAP2K1 E203Knext generation sequencingNGSpazopanibsoft tissue sarcomaSTS

Identifiers

PMID34356494
PMCPMC8301157
OpenAlexW3177637031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.